#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Bureau



## - | (1869 | 1880) | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 |

#### (43) International Publication Date 19 August 2004 (19.08.2004)

#### **PCT**

# (10) International Publication Number WO 2004/069171 A2

(51) International Patent Classification7:

**A61K** 

(21) International Application Number:

PCT/US2004/002543

(22) International Filing Date: 30 January 2004 (30.01.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/443,783

30 January 2003 (30.01.2003) US

- (71) Applicant (for all designated States except US): UNIVER-SITY OF MARYLAND, BALTIMORE [US/US]; 520 West Lombard Street, Baltimore, MD 21201-1627 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): GUILES, Ronald, D. [US/US]; 10713 Cottonwood Way, Columbia, MD 21044-1309 (US).
- (74) Agents: KIT, Gordon et al.; Sughrue Mion, PLLC, 2100 Pennsylvania Ave., NW, Suite 800, Washington, DC 20037-3213 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:


7.0

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS FOR THE TREATMENT OF SICKLE CELL DISEASE

### Cytochrome b<sub>5</sub> Hemoglobin Complex (2:1)



Proton Chemical Shift (ppm)

(57) Abstract: Compounds have been designed to inhibit the action of cytochrome b5 in the physiological re-reduction of auto-oxidized hemoglobin (methemoglobin), for the purpose of increasing methemoglobin levels in the blood of patients as a treatment for sickle cell disease. Administration of the compounds mimics congenital deficiencies in cytochrome b5, in which methemoglobin levels rise as high as 50% of total hemoglobin and derivatives in the blood, without adverse clinical manifestations. Methemoglobin inhibits red cell sickling and high levels of methemoglobin in the blood induced by the compounds of this invention prevent the symptoms of sickle cell disease.

10.0